Core Insights - Bavarian Nordic A/S reported preliminary financial results for 2025, with revenue of DKK 6,244 million, exceeding the latest guidance of approximately DKK 6,000 million [1][2] - The company achieved an EBITDA of DKK 2,542 million, resulting in an EBITDA margin of 41%, surpassing the latest guidance of approximately 40% [2][4] Financial Performance - Revenue breakdown for 2025 includes DKK 3,105 million from Public Preparedness and DKK 2,963 million from Travel Health, with Travel Health showing a 30% year-over-year growth [5][7] - The company’s core vaccines, rabies and TBE, contributed significantly to the revenue growth, with respective increases of 34% and 20% [5] - The chikungunya vaccine generated DKK 85 million in its first year of sales, exceeding guidance by DKK 10 million [5] 2026 Financial Guidance - For 2026, Bavarian Nordic expects revenue between DKK 5,000 million and DKK 5,200 million, with an EBITDA margin of approximately 25% [6][7] - Revenue from Public Preparedness is anticipated to be between DKK 1,800 million and DKK 2,000 million, with DKK 1,300 million already secured through contracts [8] - Travel Health revenue is projected at approximately DKK 3,000 million, reflecting a 10% growth over the prior year [9][10] Research and Development - R&D spending for 2026 is capped at DKK 750 million, focusing on life-cycle management of the commercial portfolio and additional studies for the chikungunya vaccine [11] - Early-stage pipeline assets are expected to enter clinical development in 2027 [11] Capital Expenditure - CAPEX for 2026 is expected to be around DKK 250 million, with inventory levels anticipated to remain relatively unchanged [12]

Core Viewpoint - Bavarian Nordic A/S has established a long-term incentive program for Executive Management and selected employees, which includes performance restricted stock units (Performance RSUs) and a warrant program as part of its Remuneration Policy [1][8]. Group 1: Performance Restricted Stock Units (Performance RSUs) - A total of 104,009 Performance RSUs are granted to members of Executive Management, with the value equating to up to 100% of their fixed annual base wage at the date of grant [2]. - Each Performance RSU is valued at DKK 188.26, based on the average market price of the company's shares on Nasdaq Copenhagen over a 15-business-day period prior to the grant [3]. - The Performance RSUs will vest in three years, contingent upon meeting specific Key Performance Indicators (KPIs) set by the Board of Directors [2]. Group 2: Warrant Program - A total of 1,270,820 warrants are granted to selected employees, allowing them to subscribe for up to 1,270,820 shares at a nominal value of DKK 10 each [4]. - The subscription price for the warrants is set at DKK 216.50 per share, which is the average market price plus a 15% premium over a 15-business-day period prior to the grant [4]. - The value of each warrant is calculated at DKK 69.52 using the Black-Scholes model, based on a share price of DKK 188.00 and a risk-free interest rate of 2.0% [5].

Core Points - Bavarian Nordic A/S has appointed Ms. Heidi Hunter as the new Vice Chair of the Board of Directors following the appointment of Anne Louise Eberhard as the new Chair [1][3] - Ms. Hunter has over 25 years of experience in the pharmaceutical industry, having held senior leadership roles at various companies including Cardinal Health, UCB, and Boehringer Ingelheim [2][3] - The Board is actively searching for additional candidates with relevant competencies to be nominated for election at the annual general meeting in April 2026 [3] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines [4] - The company is a preferred supplier of mpox and smallpox vaccines to governments, enhancing public health preparedness, and has a leading portfolio of travel vaccines [4]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Group 1 - The article does not provide any specific content related to company or industry analysis [1]

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Points - Bavarian Nordic A/S announced the immediate resignation of Chair of the Board, Luc Debruyne, with Vice Chair Anne Louise Eberhard appointed as the new Chair [1][2] - Luc Debruyne expressed gratitude for the company's achievements during his tenure and emphasized the need for the board to focus on the next phase of development [2] - Anne Louise Eberhard acknowledged Debruyne's contributions and highlighted the importance of stability and continuity in governance as the company continues its growth trajectory [3] Company Overview - Bavarian Nordic is a global vaccine company dedicated to improving health and saving lives through innovative vaccines, including mpox and smallpox vaccines [4]

Core Insights - Bavarian Nordic A/S has clarified its recent agreement with the Health Emergency Preparedness and Response Authority (HERA) regarding public preparedness initiatives [1][4] - The company has received an initial order for 750,000 doses of the MVA-BN smallpox/mpox vaccine, which will be delivered in 2026 as part of a joint procurement contract by the European Commission through HERA [2] - This order follows a previous contract option awarded by the Biomedical Advanced Research and Development Authority (BARDA) in the U.S., indicating a strong start to building a preparedness business valued at DKK 1.5-2 billion for 2026 [2] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines, particularly in the areas of mpox and smallpox [3] - The company is recognized as a preferred supplier of vaccines to governments, enhancing public health preparedness and maintaining a leading portfolio of travel vaccines [3]

Core Viewpoint - Innosera ApS has published a third supplement to its offer document, lowering the minimum acceptance condition for its takeover bid of Bavarian Nordic A/S from 75% to 66 2/3% of the voting rights and share capital [2][4]. Offer Details - The offer period has been extended, with the expiry time changed from 5:00 p.m. (CET) to 11:59 p.m. (CET) on November 5, 2025 [3]. - All other terms and conditions of the offer remain unchanged as per the previous supplements [4]. Shareholder Response - Institutional shareholders representing approximately 5.3% of Bavarian Nordic's share capital have committed to accept the improved offer during the extended period [5]. - As of October 21, 2025, the Offeror has received acceptances and binding commitments indicating a preliminary acceptance level of approximately 36.1% [5]. Regulatory Approval - The third supplement has been approved by the Danish Financial Supervisory Authority [6].

Core Viewpoint - Innosera ApS has increased its cash offer for Bavarian Nordic A/S to DKK 250 per share and extended the offer period until November 5, 2025, allowing shareholders more time to consider the offer [3][4][10]. Offer Details - The initial offer price was raised from DKK 233 to DKK 250 per share, which is stated to be the best and final offer price [3][5]. - The offer period has been extended by three weeks, now set to expire on November 5, 2025, at 5:00 p.m. (CET) [2][10]. Shareholder Response - Institutional shareholders representing approximately 5.3% of Bavarian Nordic's share capital have committed to accept the improved offer during the extended period [4]. - As of the latest update, approximately 25.7% of Bavarian Nordic's share capital has accepted the offer, indicating that the minimum acceptance condition has not yet been met [7]. Regulatory and Approval Status - The Offeror has obtained all necessary regulatory approvals for the completion of the offer, with the expectation that proceeds may be paid to shareholders by early December 2025, subject to conditions being met [6][10]. Important Dates - The updated timetable includes key dates such as the announcement of the preliminary result on November 6, 2025, and the expected settlement date for the offer price on December 3, 2025 [10][11].